ModifiedCentenePolicy CP.PHAR.43

Sapropterin Dihydrochloride (Kuvan, Javygtor, Zelvysia)

Medical necessity and prior authorization criteria for sapropterin formulations to reduce blood phenylalanine in patients with BH4-responsive phenylketonuria; applies to Centene-affiliated health plans and specified lines of business.

Policy Summary

PayerCentene

PolicySapropterin Dihydrochloride (Kuvan, Javygtor, Zelvysia) - Clinical/Medical Policy, Endocrinology

Policy CodePolicy CP.PHAR.43

Change TypeGeneric redirection addedapproval duration extended to 12 monthsnew documentation requirements

Effective Date02.01.10

Next Review Date

Key ActionSubmit prior authorization with office notes, lab results showing recent Phe >360 µmols/L, documentation of Phe-restricted diet adherence, current weight in kg, and specialist involvement.

SourceLink

POLICY UPDATE CHANGES

Added requirement for redirection from branded generics (Javygtor, later Zelvysia) to unbranded generic sapropterin.

Extended initial and continued approval duration to 12 months.

Added Sephience (and Palynziq) as agents that should not be used concomitantly with sapropterin.

Added adherence to a Phe-restricted diet as a criterion for therapy.

Added documentation requirement for member's current weight for dose calculations.

20 mg/kg/dayMaximum daily dose

12 monthsApproval duration

>360 µmols/L

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

≥1 monthFDA minimum age

addedBranded→generic redirection

Coverage Criteria for Sapropterin (PKU)

Non–FDA approved indications that are not specifically addressed in this policy will not be authorized unless there is supporting documentation of efficacy and safety consistent with the applicable off‑label use policy or the member's evidence of coverage. See the off‑label use policies referenced by the Health Plan for commercial (CP.CPA.09), ICHRA/marketplace (HIM.PA.154), and Medicaid (CP.PMN.53) lines of business for criteria that may permit coverage of off‑label uses.

Coverage under this clinical policy is subject to all terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract). Where state Medicaid provisions conflict with this clinical policy, the state Medicaid requirements take precedence. This policy is a guide to medical necessity and does not constitute a guarantee of payment.

Per the Prescribing Information, patients whose blood phenylalanine (Phe) does not decrease after up to 1 month of treatment at 20 mg/kg per day should be considered non‑responders, and therapy should be discontinued.

Dosing and Coding Key Values

Recent Phe blood level

Required recent Phe blood level> 360 µmols/L (measured within 90 days)

Context for measurementRecent Phe must be documented as part of initial approval criteria for HPA due to PKU

TimingPhe blood level must be obtained within 90 days of the request

Maximum dose

Maximum daily dose20 mg/kg per day

Dose escalation guidanceIf starting at 10 mg/kg/day and response is inadequate after up to 1 month, dose may be increased to 20 mg/kg/day

Non-responder rulePatients whose blood Phe does not decrease after 1 month of treatment at 20 mg/kg/day should discontinue therapy

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior Authorization Required

Prior authorization is required for sapropterin (Kuvan, Javygtor, Zelvysia or unbranded generic) therapies. When criteria are met, approval duration is 12 months for both initial and continued therapy.

Approval duration: 12 months for initial and continued therapy when criteria are met

Billing Rule

Branded-to-Generic Redirection

Requests for branded formulations (Kuvan, Javygtor, Zelvysia) will be redirected to the unbranded generic sapropterin. Redirection to the unbranded generic is required unless the provider documents a contraindication or clinically significant adverse effect to the unbranded generic.

Branded products affected: Kuvan, Javygtor, Zelvysia

Background and Clinical Context

Sapropterin dihydrochloride is a synthetic form of tetrahydrobiopterin (BH4), the enzyme cofactor required by phenylalanine hydroxylase. It is indicated to reduce blood phenylalanine (Phe) levels in patients with BH4‑responsive phenylketonuria (PKU) and is intended for use in conjunction with a Phe‑restricted diet. Clinical response is assessed by reduction in blood Phe following treatment.

Key Definitions and Abbreviations

tetrahydrobiopterin

DefinitionTetrahydrobiopterin (BH4) is the endogenous cofactor for phenylalanine hydroxylase; sapropterin is a synthetic form of BH4

AbbreviationBH4 stands for tetrahydrobiopterin

Role in therapyBH4 responsiveness defines suitability for sapropterin treatment to reduce blood phenylalanine

hyperphenylalaninemia

DefinitionHyperphenylalaninemia (HPA) refers to elevated blood phenylalanine levels; in this policy it denotes HPA due to BH4-responsive phenylketonuria (PKU)

AbbreviationHPA = hyperphenylalaninemia

Policy Summary

PayerCentene

PolicySapropterin Dihydrochloride (Kuvan, Javygtor, Zelvysia) - Clinical/Medical Policy, Endocrinology

Policy CodePolicy CP.PHAR.43

Change TypeGeneric redirection addedapproval duration extended to 12 monthsnew documentation requirements

Effective Date02.01.10

Next Review Date

Key ActionSubmit prior authorization with office notes, lab results showing recent Phe >360 µmols/L, documentation of Phe-restricted diet adherence, current weight in kg, and specialist involvement.

SourceLink

On This Page

Required action: Dispense unbranded generic sapropterin unless contraindicated or significant adverse effects are documented

Documentation Required

Required Documentation and Provider Responsibilities

Provider must submit documentation supporting the diagnosis and clinical need for therapy. Required documentation includes office chart notes, recent laboratory results, and evidence of specialist involvement and diet adherence.

Diagnosis documentation: confirmation of HPA due to PKU
Recent Phe blood level within 90 days showing > 360 µmols/L (for initial therapy) or evidence of reduction in Phe for continued therapy
Specialist involvement: prescribed by or in consultation with an endocrinologist, metabolic or genetic disease specialist
Diet adherence: documentation that member is currently adherent to a Phe‑restricted diet and will continue during treatment
Weight documentation: current weight in kg for dose calculation
Medication exclusions: documentation that sapropterin is not prescribed concurrently with Palynziq or Sephience

Denial Risk

Triggers for Denial

Requests missing required documentation or not meeting criteria may be denied. Providers should ensure all supporting records are submitted with the prior authorization request.

Triggers for denial include: absence of diagnosis of HPA due to PKU, missing recent Phe level (> 360 µmols/L when required), lack of specialist prescribing or consultation, no documentation of adherence to a Phe‑restricted diet, missing current weight for dosing, or concurrent use of disallowed agents (Palynziq or Sephience).
Requests for branded products without documentation of contraindication or intolerance to the unbranded generic may be redirected or denied.

Denial Risk

Denial Risk Due to Coverage Document Exclusions or State Conflicts

Coverage decisions are subject to the member's plan terms, evidence of coverage, state and federal requirements, and Health Plan administrative policies. State Medicaid provisions take precedence where applicable.

Coverage may be limited or excluded by the member's benefit plan, certificate of coverage, or state requirements
For Medicaid members, state Medicaid coverage provisions prevail if they conflict with this clinical policy
Providers should consult applicable state addendums (e.g., continuity of care rules) and plan-level requirements

HPA due to BH4-responsive PKU is the indicated condition for sapropterin used with a Phe-restricted diet

Health Plan

Definition'Health Plan' means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates

ScopeThis clinical policy guides medical necessity determinations and administration of benefits for members of the Health Plan

LimitationsCoverage decisions remain subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable state/federal requirements